Alzheimer disease trials in Israel

In Israel 9 Also abroad 815

9 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
Netanya, Petch Tikva, Ramat Gan, Rishon Le'Tzion
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Ashkelon, Jerusalem, Petah Tikva, Ramat Gan
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Ashkelon, Jerusalem, Petah Tikva, Ramat Gan
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Netanya, Petch Tikva, Ramat Gan, Rishon Le'Tzion
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 2Taking people
COMMETS- Combination MCI Metabolic Syndrome
Where
Ramat Gan
Age
60 years to 90 years
People
80
Run by
Rutgers, The State University of New Jersey
See details and how to joinNCT06072963
No phaseTaking people
Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome
Where
Tel Aviv
Age
65 years to 90 years
People
128 worldwide
Run by
Hebrew SeniorLife
See details and how to joinNCT06821568
Phase 2Enrolling by invitation
A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI
Where
Jerusalem
Age
65 years and over
People
50
Run by
Hadassah Medical Organization
See details and how to joinNCT07287852
Early phase 1Enrolling by invitation
Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?
Where
Jerusalem
Age
70 years to 80 years
People
60
Run by
Tamir Ben-Hur
See details and how to joinNCT06078891
No phaseTaking people
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
Where
Jerusalem
Age
18 years and over
People
120
Run by
Hadassah Medical Organization
See details and how to joinNCT00874783